REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH): Nasdaq/NYSE listing notice — Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.
Company requested hearing after delisting determination on Nov 11, 2025; hearing held Jan 8, 2026.
To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.
Company may implement reverse stock split if needed; warns split may not maintain price increase.
Risk of delisting remains if unable to meet deadline or other Nasdaq listing requirements.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: hearing update
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 20, 2026, the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) notified Reviva Pharmaceuticals Holdings, Inc. (the “Company”, “we” or “us”) that the Panel has granted the Company’s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) for continued listing through March 27, 2026 (the “Exception”). Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-001913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.